UBS, a Swiss bank, has reiterated its Buy rating for Novartis and set a price target of 111 francs based on insights from a recent conference.
The CFO of Novartis, Harry Kirsch, expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent.
Analyst Matthew Weston highlighted this confidence in a report released on Thursday. The report, published on November 13, 2024, emphasizes Novartis' strategic positioning as it faces upcoming patent challenges. Despite the impending patent expiration, investors are encouraged by the company's potential for sustained growth.